Table Of Contents
1 Introduction 12
1.1 Overview Of North America Advanced Wound Care Market 12
1.2 Currency And Pricing 14
1.3 Limitation 14
1.4 Markets Covered 15
2 Market Segmentation 18
2.1 Markets Covered 18
2.2 Geographic Scope 19
2.3 Years Considered For The Study 20
2.4 Currency And Pricing 20
2.5 Research Methodology 21
2.6 Primary Interviews With Key Opinion Leaders 24
2.7 Secondary Sources 25
2.8 Assumptions 25
3 Market Overview 26
3.1 Drivers 28
3.1.1 Rising Ageing And Geriatric Population 28
3.1.2 Technological Advancement 28
3.1.3 Government Support 29
3.1.4 Rising Incidences Of Chronic Wound 30
3.1.5 Increasing Trend 31
3.2 Restraints 31
3.2.1 Low Awareness 31
3.2.2 Slow Growth Rate And Shrinking Market 32
3.2.3 Complex Regulatory Approval Process 32
3.2.4 Competition With Other Moist Dressings 33
3.3 Opportunities 33
3.3.1 Reimbursement 33
3.3.2 Mergers And Acquisitions To Expand Business 34
3.3.3 Unmet Needs 34
3.3.4 Increasing Demand 35
3.4 Challenges 35
3.4.1 Shortage Of Trained Staff 35
3.4.2 The Development Of Substitute Products 35
3.5 Key Market Trends And Upcomming Technologies 36
3.5.1 Smart Dressing Will Push Future Growth 36
3.5.2 Hydrofiber Has Been The Most Significant Recent Innovation 36
3.5.3 Alginate Dressing Is Expected To Grow Robustly In The Upcoming Years 36
3.5.4 Foam Dressing Accounting The Largest Market Segment In The Upcoming Years 36
4 Executive Summary 37
5 Premium Insights 40
6 North America Advanced Wound Care Market, By Product Type 43
6.1 Overview 44
6.2 Dressing 46
6.2.1 Dressing On The Basis Of Product Type 47
6.2.1.1 Film Dressings 47
6.2.1.2 Foam Dressings 48
6.2.1.3 Hydrogels 48
6.2.1.4 Alginates 49
6.2.1.5 Wound Contact Layer 49
6.2.1.6 Super Absorbent Dressing 50
6.3 Biologics 51
6.3.1 Biologics On The Basis Of Product Type 51
6.3.1.1 Allografts 52
6.3.1.2 Synthetic Skin Grafts 52
6.3.1.3 Xenografts 52
6.3.1.4 Growth Factors 53
6.3.1.4.1 Platelet Derived Growth Factor (Pdgf) 53
6.3.1.4.2 Platelet Rich Plasma (Prp) 53
6.3.1.4.3 Epidermal Growth Factors (Egf) 55
6.3.1.4.4 Basic Fibroblast Growth Factors (Bfgf) 55
6.3.1.4.5 Granulocyte Colony Stimulating Factor (G-Csf) 55
6.3.1.4.6 Talactoferrin Alfa 56
6.3.1.4.7 Thrombin Peptide 56
6.3.1.4.8 Keratinocy Growth Factor (Kgf) 56
6.4 Therapy Devices 57
6.4.1 Therapy Devices On The Basis Of Product Type 57
6.4.1.1 Negative Pressure Wound Therapy (Npwt) 58
6.4.1.1.1 Portable Npwt Devices 58
6.4.1.1.2 Disposable Npwt Devices 59
6.4.1.2 Pressure Relief Devices 59
6.4.1.3 Hyperbaric Oxygen Chambers 59
6.4.1.3.1 Monoplace 59
6.4.1.3.2 Multiplace 60
6.4.1.3.3 Topical 60
6.4.1.4 Wound Debridement Devices 61
6.4.1.4.1 Hydrosurgical 61
6.4.1.4.2 Ultrasound 61
6.4.1.4.3 Mechanical 61
6.4.1.4.4 Others 61
6.4.1.5 Physical Therapies 62
6.4.1.5.1 Laser Therapy 62
6.4.1.5.2 Electrical Stimulation 62
6.4.1.5.3 External Shock Wave Therapies 63
6.4.1.5.4 Saline Mist Therapy 63
7 North America Advanced Wound Care Market, By Wound Type 64
7.1 Introduction 65
7.2 Surgical Wound 67
7.2.1 Class I 67
7.2.2 Class Ii 67
7.2.3 Class Iii 67
7.2.4 Class Iv 67
7.3 Diabetic Ulcers 68
7.4 Pressure Ulcers 69
7.5 Venous Ulcers 70
7.6 Burns 70
8 North America Advanced Wound Care Market, By End User 71
8.1 Overview 72
8.2 Hospitals 73
8.3 Wound Care Centers 73
8.4 Ambulatory Centers 73
8.5 Home Healthcare 73
8.6 Clinics 74
8.7 Community Healthcare 74
9 North America Advanced Wound Care Market, By Distribution Channel 75
9.1 Overview 76
9.2 Direct Tenders 76
9.3 Retail 76
10 North America Advanced Wound Care Market By Geography 77
10.1 North America 77
10.1.1 U.S. 90
10.1.2 Canada 97
10.1.3 Mexico 104
11 North America Advanced Wound Care Market, Company Share 111
11.1 Company Share Analysis; North America 111
12 Company Profile 112
12.1 Acelity L.P. Inc. (Subsidary Of Allargan) 112
12.1.1 Company Overview 112
12.1.2 Company Share Analysis 112
12.1.3 Product Portfolio 113
12.1.4 Recent Developments 115
12.2 Smith And Nephew 116
12.2.1 Company Overview 116
12.2.2 Company Share Analysis 116
12.2.3 Revenue Analysis 117
12.2.4 Product Portfolio 117
12.2.5 Recent Developments 118
12.3 Molnlycke Healthcare 119
12.3.1 Company Overview 119
12.3.2 Company Share Analysis 119
12.3.3 North America Presence 120
12.3.4 Product Portfolio 120
12.3.5 Recent Developments 121
12.4 3M 122
12.4.1 Company Overview 122
12.4.2 Company Share Analysis 122
12.4.3 Revenue Analysis 123
12.4.4 Product Portfolio 123
12.4.5 Recent Developments 125
12.5 Baxter 126
12.5.1 Company Overview 126
12.5.2 Revenue Analysis 126
12.5.3 Product Portfolio 127
12.5.4 Recent Developments 127
12.6 Coloplast 128
12.6.1 Company Overview 128
12.6.2 Revenue Analysis 128
12.6.3 Product Portfolio 129
12.6.4 Recent Developments 129
12.7 Convatec Inc. 130
12.7.1 Company Overview 130
12.7.2 Revenue Analysis 130
12.7.3 Product Portfolio 131
12.7.4 Recent Developments 132
12.8 Derma Sciences Inc (Subsidiary Of Integra Life Sciences) 133
12.8.1 Company Overview 133
12.8.2 North America Presence 133
12.8.3 Product Portfolio 133
12.8.4 Recent Developments 135
12.9 Ethicon Inc (Subsidiary Of Johnson And Johnson Services, Inc ) 136
12.9.1 Company Overview 136
12.9.2 North America Presence 136
12.9.3 Product Portfolio 137
12.9.4 Recent Developments 137
12.10 Integra Life Sciences Corporation 138
12.10.1 Company Overview 138
12.10.2 Revenue Analysis 138
12.10.3 Product Portfolio 139
12.10.4 Recent Developments 140
12.11 Paul Hartmann Limited 141
12.11.1 Company Overview 141
12.11.2 Revenue Analysis 141
12.11.3 Product Portfolio 142
12.11.4 Recent Development 142
12.12 Organogenesis Inc 143
12.12.1 Company Overview 143
12.12.2 North America Presence 143
12.12.3 Product Portfolio 144
12.12.4 Recent Developments 144
13 Related Reports 145